Nisa Investment Advisors LLC reduced its stake in Teleflex Incorporated (NYSE: TFX – Get Rating) by 7.2% in the fourth quarter, according to its latest Form 13F filed with the Securities and Exchange Commission. Institutional investors owned 11,061 shares in the medical technology company after selling 854 shares during the period. Nisa Investment Advisors LLC’s stake in Teleflex was valued at $2,761,000 as of the latest SEC filing.
Several other large investors have also recently changed positions in the business. Utah Retirement Systems increased his stake in Teleflex stock by 0.6% in the third quarter. Utah Retirement Systems now owns 8,368 shares of the medical technology company worth $1,686,000 after purchasing an additional 47 shares during this period. Tealwood Asset Management Inc. increased his stake in Teleflex stock by 1.6% in the third quarter. After purchasing an additional 48 shares during this period, Tealwood Asset Management Inc. now owns 3,138 shares of the medical technology company worth $632,000. Mercer Global Advisors Inc. ADV increased his stake in Teleflex shares by 3.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 1,411 shares of the medical technology company valued at $284,000 after purchasing an additional 48 shares during this period. Ensign Peak Advisors Inc increased its stake in Teleflex by 0.3% in the third quarter. Ensign Peak Advisors Inc now owns 16,692 shares of the medical technology company valued at $3,362,000 after acquiring an additional 50 shares during the previous quarter. Finally, Cambridge Investment Research Advisors Inc. increased Teleflex shares by 2.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 2,231 shares in a medical technology company valued at $792,000 after acquiring an additional 54 shares during the previous quarter. Institutional investors and hedge funds own 93.82% of the company’s shares.
Teleflex trading down 0.4 %
NYSE:TFX shares opened Wednesday at $268.34. Teleflex Incorporated hit a 52-week low of $182.65 and a 52-week high of $325.99. The company has a market capitalization of $12.6 billion, a PE ratio of 34.94, a P/E/G ratio of 2.82 and a beta of 0.99. The company has a 50-day moving average price of $246.88 and a 200-day moving average price of $236.63. The company has a quick ratio of 1.43, a current ratio of 2.43 and a debt to equity ratio of 0.40.
Teleflex (NYSE:TFX – Get Rating) last reported quarterly results on Thursday, Feb. 23. The medical technology company reported his EPS of $3.52 for the quarter, beating analysts’ consensus forecast of $3.44 by $0.08. Teleflex had a net profit margin of 13.01% and a return on equity of 15.87%. The company posted revenue of $758 million for the quarter, compared to consensus expectations of $760.29 million. During the same period last year, the company earned him $3.60 in EPS. Teleflex revenues were down 0.5% year-on-year. Sell-side analysts expect Teleflex Incorporated to post earnings per share of 13.29 for the current year.
Announcement of Teleflex Dividend
The business recently announced a quarterly dividend, which was paid out on Wednesday, March 15th. Shareholders of record on Friday, March 3 were awarded a dividend of $0.34 per share. The ex-dividend date was Thursday, March 2nd. This represents his $1.36 dividend and 0.51% dividend yield on an annual basis. Teleflex has a Dividend Payout Ratio (DPR) of 17.71%.
Wall Street analyst opinion
Many research analysts comment on stocks. Stevens raised his price target on Teleflex shares from his $280.00 to his $295.00, giving the company an “overweight” rating in a research note on Wednesday, Dec. 28. Morgan Stanley raised its price target on Teleflex stock from her $236.00 to her $280.00, giving the company an “equal-weighted” rating in its research notes on Friday, Jan. 6. Raymond James raised his price target on Teleflex shares from his $231.00 to his $259.00, giving the company an “excellent” rating in a research note on Friday, Feb. 24. Truist Financial raised its price target on Teleflex stock from $250.00 to $264.00, giving it a “Hold” rating in its research report on Monday, April 17. Finally, StockNews.com downgraded Teleflex’s stock from a ‘buy’ rating to a ‘hold’ rating in his Friday March 31 report. Seven analysts rated the stock with a hold rating and six assigned a buy rating to the company’s stock. Based on MarketBeat.com data, the company’s current average valuation is “pending” with a consensus price target of $275.08.
Teleflex, Inc provides medical technology products that enable healthcare providers to improve patient outcomes and increase patient and healthcare provider safety. The company designs, develops, manufactures and supplies disposable medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgery.
Want to know other hedge funds holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trading from Teleflex Incorporated (NYSE:TFX – Get Rating).
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to firstname.lastname@example.org.
Listen to this before considering Teleflex.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks top analysts are quietly whispering to customers to buy now before the broader market catches on…and Teleflex wasn’t on the list.
Teleflex currently has a ‘moderate buy’ rating among analysts, but the top rated analysts believe these five stocks are better buys.
See 5 stocks here